J&J submits rilpivirine MAA

Johnson & Johnson (NYSE:JNJ) submitted an MAA to the European Medicines Agency for rilpivirine ( TMC278) for use in combination with other antiretroviral agents to treat HIV in treatment-naive adults. Concurrently, partner Gilead Sciences Inc. (NASDAQ:GILD) submitted an application to EMA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir for HIV. The companies partnered to develop a fixed-dose combination of the two products last year. ...